Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 281

1.

[Focus on the screening for prostate cancer by PSA].

Roumeguère T, Van Velthoven R.

Rev Med Brux. 2013 Sep;34(4):311-9. Review. French.

PMID:
24195246
2.

Screening for prostate cancer: the current evidence and guidelines controversy.

Gomella LG, Liu XS, Trabulsi EJ, Kelly WK, Myers R, Showalter T, Dicker A, Wender R.

Can J Urol. 2011 Oct;18(5):5875-83. Review.

3.

American Urological Association (AUA) guideline on prostate cancer detection: process and rationale.

Carter HB.

BJU Int. 2013 Sep;112(5):543-7. doi: 10.1111/bju.12318. Review.

4.

Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.

Faria EF, Carvalhal GF, dos Reis RB, Tobias-Machado M, Vieira RA, Reis LO, Nogueira L, Machado RD, Freitas CH Jr, Magnabosco WJ, Mauad EC, Carvalho AL.

BJU Int. 2012 Dec;110(11 Pt B):E653-7. doi: 10.1111/j.1464-410X.2012.11398.x. Epub 2012 Aug 14.

5.

Prostate-specific antigen testing and prostate cancer screening.

Djavan B, Eckersberger E, Finkelstein J, Sadri H, Taneja SS, Lepor H.

Prim Care. 2010 Sep;37(3):441-59, vii. doi: 10.1016/j.pop.2010.05.001. Review.

PMID:
20705192
6.

Impact of the 2012 United States Preventive Services Task Force statement on prostate-specific antigen screening: analysis of urologic and primary care practices.

Perez TY, Danzig MR, Ghandour RA, Badani KK, Benson MC, McKiernan JM.

Urology. 2015 Jan;85(1):85-9. doi: 10.1016/j.urology.2014.07.072. Epub 2014 Nov 11.

PMID:
25440819
7.

Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers.

Ferro M, Bruzzese D, Perdonà S, Mazzarella C, Marino A, Sorrentino A, Di Carlo A, Autorino R, Di Lorenzo G, Buonerba C, Altieri V, Mariano A, Macchia V, Terracciano D.

Clin Chim Acta. 2012 Aug 16;413(15-16):1274-8. doi: 10.1016/j.cca.2012.04.017. Epub 2012 Apr 20.

PMID:
22542564
8.

Cost-effectiveness of Prostate Health Index for prostate cancer detection.

Nichol MB, Wu J, Huang J, Denham D, Frencher SK, Jacobsen SJ.

BJU Int. 2012 Aug;110(3):353-62. doi: 10.1111/j.1464-410X.2011.10751.x. Epub 2011 Nov 11.

9.

Response to the U.S. Preventative Services Task Force decision on prostate cancer screening.

Makovey I, Stephenson AJ, Haywood S.

Curr Urol Rep. 2013 Jun;14(3):168-73. doi: 10.1007/s11934-013-0318-9.

PMID:
23568623
10.

Incidence of insignificant prostate cancer using free/total PSA: results of a case-finding protocol on 14,453 patients.

Pepe P, Aragona F.

Prostate Cancer Prostatic Dis. 2010 Dec;13(4):316-9. doi: 10.1038/pcan.2010.29. Epub 2010 Aug 17.

PMID:
20714341
11.

Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.

Mäkinen T, Tammela TL, Hakama M, Stenman UH, Rannikko S, Aro J, Juusela H, Määttänen L, Auvinen A.

J Urol. 2001 Oct;166(4):1339-42.

PMID:
11547069
12.

Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study.

Lazzeri M, Haese A, de la Taille A, Palou Redorta J, McNicholas T, Lughezzani G, Scattoni V, Bini V, Freschi M, Sussman A, Ghaleh B, Le Corvoisier P, Alberola Bou J, Esquena Fernández S, Graefen M, Guazzoni G.

Eur Urol. 2013 Jun;63(6):986-94. doi: 10.1016/j.eururo.2013.01.011. Epub 2013 Jan 24.

PMID:
23375961
13.

Prostate Cancer Screening and the Associated Controversy.

Tabayoyong W, Abouassaly R.

Surg Clin North Am. 2015 Oct;95(5):1023-39. doi: 10.1016/j.suc.2015.05.001. Epub 2015 Jun 23. Review.

PMID:
26315521
14.

A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.

Auprich M, Augustin H, Budäus L, Kluth L, Mannweiler S, Shariat SF, Fisch M, Graefen M, Pummer K, Chun FK.

BJU Int. 2012 Jun;109(11):1627-35. doi: 10.1111/j.1464-410X.2011.10584.x. Epub 2011 Sep 21.

15.

On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer.

Bangma CH, van Schaik RH, Blijenberg BG, Roobol MJ, Lilja H, Stenman UH.

Eur J Cancer. 2010 Nov;46(17):3109-19. doi: 10.1016/j.ejca.2010.09.031.

PMID:
21047594
16.

The Cost-Effectiveness of Prostate Cancer Detection with the Use of Prostate Health Index.

Heijnsdijk EA, Denham D, de Koning HJ.

Value Health. 2016 Mar-Apr;19(2):153-7. doi: 10.1016/j.jval.2015.12.002. Epub 2016 Jan 14.

17.

Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.

Hattangadi JA, Chen MH, D'Amico AV.

BJU Int. 2012 Dec;110(11):1636-41. doi: 10.1111/j.1464-410X.2012.11354.x. Epub 2012 Jul 3.

18.

Applying strategies from libertarian paternalism to decision making for prostate specific antigen (PSA) screening.

Wheeler DC, Szymanski KM, Black A, Nelson DE.

BMC Cancer. 2011 Apr 21;11:148. doi: 10.1186/1471-2407-11-148.

19.

The Memorial Sloan Kettering Cancer Center Recommendations for Prostate Cancer Screening.

Vickers AJ, Eastham JA, Scardino PT, Lilja H.

Urology. 2016 May;91:12-8. doi: 10.1016/j.urology.2015.12.054. Epub 2016 Feb 2.

20.

The effect of lowering the prostate-specific antigen normal cutoff on referral rates to urology.

Shenker BS, Stern J.

J Am Board Fam Med. 2012 Nov-Dec;25(6):927-9. doi: 10.3122/jabfm.2012.06.120172.

Supplemental Content

Support Center